Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

hI-con1

Next Previous
X
Search
Drug Profile

hI-con1

Alternative Names: hI-con1; hIcon1; human Immuno-conjugate 1; ICON-1; Immuno-conjugate-1

Latest Information Update: 05 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yale University
  • Developer Iconic Therapeutics; Yale University
  • Class Antineoplastics; Drug conjugates; Eye disorder therapies; Immunoconjugates; Immunoproteins; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunostimulants; Natural killer cell stimulants; Thromboplastin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer; Solid tumours; Uveal melanoma; Wet age-related macular degeneration

Most Recent Events

  • 30 Nov 2022 Discontinued - Phase-I for Uveal melanoma in USA (Intravitreous) (Iconic Therapeutics and Endpoint Health website, November 2022).
  • 30 Nov 2022 Discontinued - Phase-II for Wet age-related macular degeneration (Combination therapy, In the elderly, In adults) in USA (Intravitreous) (Iconic Therapeutics and Endpoint Health website, November 2022).
  • 30 Nov 2022 Discontinued - Phase-II for Wet age-related macular degeneration (In the elderly, In adults) in USA (Intravitreous) (Iconic Therapeutics and Endpoint Health website, November 2022).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top